Search

Your search keyword '"Crusoe, Edvan"' showing total 96 results
Start Over "Crusoe, Edvan" Language english
96 results on '"Crusoe, Edvan"'

1. COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)

Author

Garnica, Marcia, Crusoe, Edvan De Queiroz, Ribeiro, Glaciano, Bittencourt, Rosane, Magalhães, Roberto José Pessoa, Zanella, Karla Richter, Hallack Neto, Abrahão Elias, Lima, Juliana Souza, Solo, Caroline Bonamin, Souza, Emmanuella Graciott, Fernandes, Andre Magalhaes, Maiolino, Angelo, and Hungria, Vania

Published
2024
Full Text
View/download PDF

4. Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2022. Part I

Author

Maiolino, Angelo, Crusoé, Edvan de Queiroz, Martinez, Gracia Aparecida, Braga, Walter Moisés Tobias, de Farias, Danielle Leão Cordeiro, Bittencourt, Rosane Isabel, Neto, Jorge Vaz Pinto, Ribeiro, Glaciano Nogueira, Bernardo, Wanderley Marques, Tristão, Luca, Magalhaes, Roberto J.P., and Hungria, Vânia Tietsche de Moraes

Published
2022
Full Text
View/download PDF

5. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis

Author

Jurczyszyn, Artur, Castillo, Jorge J., Olszewska-Szopa, Magdalena, Kumar, Lalit, Thibaud, Santiago, Richter, Joshua, Flicker, Kari, Fiala, Mark, Vij, Ravi, Yi, Shuhua, Xu, Fang, Silbermann, Rebecca, Gaisan, Carmen Montes, Ocio, Enrique M., Waszczuk-Gajda, Anna, Crusoe, Edvan De Queiroz, Salomon-Perzyński, Aleksander, Hus, Iwona, Valls, Julio Davila, Gozzetti, Alessandro, Czepiel, Jacek, Krzanowska, Katarzyna, Chappell, Aimee, Chellapuram, S.K, Suska, Anna, and Vesole, David H.

Published
2022
Full Text
View/download PDF

9. Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

Author

Crusoe, Edvan De Queiroz, Higashi, Fabiana, Martinez, Gracia, Bittencourt, Rosane, Pinto Neto, Jorge Vaz, Sousa, Lais, Santucci, Rodrigo, Magalhães, Roberto José Pessoa, Colli, Gilberto, Nunes, Renata Ferreira Marques, Ribeiro, Glaciano, Nicacio, Jandir, Zanella, Karla Richter, Kutner, Jose Mauro, Magalhaes, Andre, Leao, Danielle, Hallack Neto, Abrahão Elias, Braga, Walter, Souza, Emanuella G, Guimaraes, Antonio Julio A.M., Durigon, Giovanna Steffenello, Laks, Dani, Maiolino, Angelo, and Hungria, Vania Tietsche de Moraes

Published
2020
Full Text
View/download PDF

12. Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries

Author

Pessoa de Magalhães Filho, Roberto José, Crusoe, Edvan, Riva, Eloisa, Bujan, Willen, Conte, Guilhermo, Navarro Cabrera, Juan Ramon, Garcia, Diana Katerine, Vega, Guilhermo Quintero, Macias, Jose, Oliveros Alvear, Jose Willian, Royg, Mercedes, Neves, Lidiane Andino, Lopez Dopico, Jose Luis, Espino, German, Ortiz, Douglas Rosales, Socarra, Zurelis, Fantl, Dorotea, Ruiz-Arguelles, Guillermo J., Maiolino, Angelo, Hungria, Vania Tietsche de Moraes, Harousseau, Jean-Luc, and Durie, Brian

Published
2019
Full Text
View/download PDF

14. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries

Author

Hungria, Vania T. M., Lee, Jae Hoon, Maiolino, Angelo, de Queiroz Crusoe, Edvan, Martinez, Gracia, Bittencourt, Rosane, Duarte, Gislaine Oliveira, Fantl, Dorotea Beatriz, Navarro, Juan Ramon, Conte, Guillermo, Gomez-Almaguer, David, Ruiz-Argüelles, Guillermo J., Kim, Kihyun, Shimizu, Kazuyuki, Chen, Wenming, Huang, Shang-YI, Chng, Wee-Joo, Chim, Chor Sang, Nawarawong, Weerasak, and Durie, Brian

Published
2019
Full Text
View/download PDF

17. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study

Author

Jurczyszyn, Artur, Gozzetti, Alessandro, Gdula-Argasińska, Joanna, Czepiel, Jacek, Vij, Ravi, Fiala, Mark, Valls, Davila Julio, Mądry, Krzysztof, Waszczuk-Gajda, Anna, Grosicki, Sebastian, Barchnicka, Agnieszka, Crusoe, Edvan, Hungria, Vania, Gentile, Massimo, Mele, Giuseppe, Ksieniewicz, Marcin, Vesole, David H., and Castillo, Jorge J.

Published
2017
Full Text
View/download PDF

18. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.

Author

Avivi, Irit, Vesole, David H., Davila-Valls, Julio, Usnarska-Zubkiewicz, Lidia, Olszewska-Szopa, Magdalena, Milunovic, Vibor, Baumert, Bartłomiej, Osękowska, Bogumiła, Kopińska, Anna, Gentile, Massimo, Puertas-Martinez, Borja, Robak, Paweł, Crusoe, Edvan, Rodriguez-Lobato, Luis Gerardo, Gajewska, Małgorzata, Varga, Gergely, Delforge, Michel, Cohen, Yael, Gozzetti, Alessandro, and Pena, Camila

Subjects
THERAPEUTIC use of antineoplastic agents, HEMOGLOBINS, RETROSPECTIVE studies, ACQUISITION of data, CANCER patients, RISK assessment, TREATMENT effectiveness, TUMOR classification, SECONDARY primary cancer, MEDICAL records, DESCRIPTIVE statistics, MULTIPLE myeloma, DISEASE risk factors
Abstract

Simple Summary: The emergence of new therapeutic agents for multiple myeloma (MM) over the last 2 decades has resulted in a significant improvement in overall survival (OS). However, this improvement might be associated with the increased incidence of second primary malignancies (SPMs). Most studies in the field reviewed patients that participated in phase 2–3 clinical studies, focusing on the incidence of SPMs. The current study evaluated the characteristics, management, and outcomes of MM patients diagnosed with SPMs outside clinical studies. In our study, we present real-world data of 165 MM patients that were diagnosed with SPM during the course of their disease; we offer detailed data on SPM characteristics and management, as well as valuable insights into the management of MM post-SPM detection and the actual prognosis of MM patients following SPM diagnosis. Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational 'real-world' retrospective study analyzed the characteristics and outcomes of MM patients that developed SPMs. Results: 165 patients were analyzed: 62.4% males; 8.5% with a prior cancer; 113 with solid SPMs, mainly ≥stage 2; and 52 with hematological SPM (hemato-SPM), mainly MDS/AML. Patients with hemato-SPM were younger (p = 0.05) and more frequently had a prior AutoHCT (p = 0.012). The time to SPM was shorter in the older (>65 years) and more heavily pretreated patients. One hundred patients were actively treated at the time of SPM detection. Treatment was discontinued in 52, substituted with another anti-MM therapy in 15, and continued in 33 patients. Treatment discontinuation was predominant in the patients diagnosed with hemato-SPM (76%). The median OS following SPM detection was 8.5 months, and the main cause of death was SPM. A poor ECOG status predicted a shorter OS (PS 3 vs. 0, HR = 5.74, 2.32–14.21, p < 0.001), whereas a normal hemoglobin level (HR = 0.43, 0.19–0.95, p = 0.037) predicted longer OS. Conclusions: With the continuing improvement in OS, a higher proportion of MM patients might develop SPM. The OS following SPM diagnosis is poor; hence, frequent surveillance and early detection are imperative to improve outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. The Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and its absolute commitment to ethics and absence of conflicts of interest

Author

de Souza, Carmino Antonio, Rego, Eduardo Magalhães, Ribeiro, Glaciano Nogueira, Magalhães, Silvia Maria Meira, da Silva, Celso Arrais Rodrigues, Passos, Leny Nascimento da Motta, Covas, Dimas Tadeu, Tavares, Renato Sampaio, Hungria, Vania T.de Moraes, Crusoé, Edvan de Queiroz, Marques, José Francisco Comenalli, Jr, Chiattone, Carlos Sérgio, Langhi, Dante, Junior, Neto, Jorge Vaz Pinto, Laforga, Violete Petitto, and Maiolino, Angelo

Published
2024
Full Text
View/download PDF

22. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

Author

Jurczyszyn, Artur, Grzasko, Norbert, Gozzetti, Alessandro, Czepiel, Jacek, Cerase, Alfonso, Hungria, Vania, Crusoe, Edvan, Silva Dias, Ana Luiza Miranda, Vij, Ravi, Fiala, Mark A., Caers, Jo, Rasche, Leo, Nooka, Ajay K., Lonial, Sagar, Vesole, David H., Philip, Sandhya, Gangatharan, Shane, Druzd-Sitek, Agnieszka, Walewski, Jan, Corso, Alessandro, Cocito, Federica, Vekemans, Marie-Christine M., Atilla, Erden, Beksac, Meral, Leleu, Xavier, Davila, Julio, Badros, Ashraf, Aneja, Ekta, Abildgaard, Niels, Kastritis, Efstathios, Fantl, Dorotea, Schutz, Natalia, Pika, Tomas, Butrym, Aleksandra, Olszewska-Szopa, Magdalena, Usnarska-Zubkiewicz, Lidia, Usmani, Saad Z., Nahi, Hareth, Chim, Chor S, Shustik, Chaim, Madry, Krzysztof, Lentzsch, Suzanne, Swiderska, Alina, Helbig, Grzegorz, Guzicka-Kazimierczak, Renata, Lendvai, Nikoletta, Waage, Anders, Andersen, Kristian T., Murakami, Hirokazu, Zweegman, Sonja, and Castillo, Jorge J.

Published
2016
Full Text
View/download PDF

25. Real World Evidence- the Proportion of Myeloma Patients' Death Due to Early Progression

Author

Crusoe, Edvan de Queiroz, Ribeiro, Glaciano, Perobelli, Leila, Zanella, Karla, Souza, Emanuella Graciott, Centrone, Renato, Higashi, Fabiana, Bittencourt, Rosane, Moreno, Fabio, Saraiva, Joao, Magalhaes Filho, Roberto Pessoa, Moura, Fernanda Lemos, Cantadori, Lucas Oliveira, Maciel, James, Sola, Caroline Bonamin, Hallack Neto, Abrahão Elias, Ovigli Silva Lopes, Danielle C., Araujo, Cleder Aparecido Da Silva Da Silva, Braga, Walter Moisés Tobias, Herriot, Luciana Barreto, Gusmao, Breno, Martinez, Gracia, Soares, Luiza, Vaz, Jorge, Maiolino, Angelo, and Hungria, Vania T.M

Published
2023
Full Text
View/download PDF

27. Equity program: strategies on clinical studies as an aggregating potential

Author

Crusoe, Edvan de Queiroz, Hallack Neto, Abrahão Elias, Nantes, Deise Ferreira, Ribeiro, Eduardo Flavio Oliveira, Pinto, Fernando Monteiro Correia, Bortolini, Jaisson Andre Pagnoncelli, Maciel, James Farley Rafael, Marques Junior, Jose Francisco Comenalli, Corrêa, Lorena Costa, Capra, Marcelo Eduardo Zanella, Carvalho, Maria do Perpétuo Socorro Sampaio, de Melo, Nelcivone Soares, Quintas, Rafaela Vasques de Oliveira, Carneiro, Thiago Xavier, Laforga, Violete Petitto, and Cunha, Renato Luiz Guerino

Published
2023
Full Text
View/download PDF

30. SOHO State of the Art Updates and Next Questions: Pathology and Pathogenesis of Nodal Peripheral T-Cell Lymphomas.

Author

Jurczyszyn, Artur, Castillo, Jorge J., Olszewska-Szopa, Magdalena, Kumar, Lalit, Thibaud, Santiago, Richter, Joshua, Flicker, Kari, Fiala, Mark, Vij, Ravi, Yi, Shuhua, Xu, Fang, Silbermann, Rebecca, Gaisan, Carmen Montes, Ocio, Enrique M., Waszczuk-Gajda, Anna, Crusoe, Edvan De Queiroz, Salomon-Perzynski, Aleksander, Hus, Iwona, Valls, Julio Davila, and Gozzetti, Alessandro

Published
2022
Full Text
View/download PDF

32. Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

Author

De Queiroz Crusoe, Edvan, Leal, Joanna, Santos, Juliana Andrade, Santos, Herbert Henrique de Melo, Santos, Allan de souza, Lucas, Larissa Ferreira, Almeida, Alessandro de M., Chaves, Marcos, Dutra, Daniela Dourado, Hungria, Vania T.M., Salvino, Marco Aurelio, and Arruda, Maria da Gloria B.

Published
2022
Full Text
View/download PDF

33. P-130: Brazilian ineligible multiple myeloma patients: real world data from a prospective multicenter platform

Author

Crusoe, Edvan, Ribeiro, Glaciano, Zanella, Karla, Perobelli, Leila, Centrone, Renato, Souza, Emanuella, Bittencourt, Rosane, Magalhaes, Roberto, Moreno, Fabio, Saraiva, Joao, Cantadori, Lucas, Ovigli, Danielle, Higashi, Fabiana, araujo, Cleder, Braga, Walter, Gusmao, Breno, Hallack, Abrahao, Sola, Caroline, Matinez, Gracia, Castro, Nelson, Souto, Joao, Soares, Luiza, Mattos, Ederson, Maiolino, Angelo, and Hungria, Vania

Published
2022
Full Text
View/download PDF

35. COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)

Author

Garnica, Marcia, De Queiroz Crusoe, Edvan, Ribeiro, Glaciano, Bittencourt, Rosane, Magalhães, Roberto José Pessoa, Zanella, Karla Richter, Hallack Neto, Abrahão Elias, Lima, Juliana, Sola, Caroline, Souza, Emmanuella G, Magalhaes, Andre, Maiolino, Angelo, and Hungria, Vania

Published
2021
Full Text
View/download PDF

36. Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

Author

De Queiroz Crusoe, Edvan, Leal, Joanna, Salvino, Marco Aurelio, Lucas, Larissa Ferreira, Santos, Juliana Andrade, Santos, Herbert Henrique de Melo, Almeida, Alessandro de M., Santos, Allan de souza, Chaves, Marcos, Santos, Mariane Melo, Silva, Sarah Queiroz, Vieira, Lucas de Oliveira, Fonseca, Cleverson Alves, Adorno, Elisangela, Hungria, Vania, and Arruda, Maria da Gloria B.

Published
2021
Full Text
View/download PDF

37. P-173: Impact of Daratumumab (DARA) administration during transplant-eligible newly diagnosed Multiple Myeloma (TE NDMM) induction on stem cell (SC) mobilization count and post-transplant engraftment

Author

Crusoe, Edvan, Almeida, Alessandro, Chaves, Marcos, Salvino, Marco, Nicanor, Jamile, Leal, JOanna, Santos, Herbert, Santos, Allan, Guimaraes, Victor, Dourado, Daniela, Lucas, Larissa, Santos, Mariane, santos, Juliana, and da Gloria Arruda, Maria

Published
2021
Full Text
View/download PDF

38. P-172: Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results

Author

Crusoe, Edvan, santos, Juliana, Leal, JOanna, Santos, Herbert, santos, Allan, Almeida, Alessandro, Santos, Mariane, Lucas, Larissa, Queiroz, Sarah, Fonseca, Cleverson, Adorno, Elisangela, Vieira, Lucas, Hungria, Vania, Salvino, Marco, and da Gloria Arruda, Maria

Published
2021
Full Text
View/download PDF

39. IgM myeloma: A multicenter retrospective study of 134 patients

Author

Castillo, Jorge J., Jurczyszyn, Artur, Brozova, Lucie, Crusoe, Edvan, Czepiel, Jacek, Davila, Julio, Dispenzieri, Angela, Eveillard, Marion, Fiala, Mark A., Ghobrial, Irene M., Gozzetti, Alessandro, Gustine, Joshua N., Hajek, Roman, Hungria, Vania, Jarkovsky, Jiri, Jayabalan, David, Laubach, Jacob P., Lewicka, Barbara, Maisnar, Vladimir, Manasanch, Elisabet E., Moreau, Philippe, Morgan, Elizabeth A., Nahi, Hareth, Niesvizky, Ruben, Paba-Prada, Claudia, Pika, Tomas, Pour, Ludek, Reagan, John L., Richardson, Paul G., Shah, Jatin, Spicka, Ivan, Vij, Ravi, Waszczuk-Gajda, Anna, and Gertz, Morie A.

Subjects
Aged, 80 and over, Adult, Male, Aged, Biomarkers, Bone Marrow, Bone and Bones, Combined Modality Therapy, Female, Humans, Immunoglobulin M, Middle Aged, Multiple Myeloma, Plasma Cells, Retrospective Studies, Survival Analysis, Treatment Outcome, Hematology, 80 and over
Abstract

IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL

Published
2017

40. P954: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY.

Author

Hungria, Vania, Gaiolla, Rafael, Galvez, Kenny, Remaggi, Guillermina, Schutz, Natalia, Bittencourt, Rosane, Maiolino, Angelo, Quintero, Guillermo, Silvana Cugliari, Maria, Moises Tobias, Walter, Colaco Villarim, Carolina, Crusoe, Edvan, Ines Enrico, Alicia, Pei, Huiling, Fernandez, Mariana, Saes, Jaqueline, and Trufelli, Damila

Published
2023
Full Text
View/download PDF

41. Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Author

De Queiroz Crusoe, Edvan, Salvino, Marco Aurelio, Silva, Sarah Queiroz, Santos, Herbert Henrique de Melo, Santos, Allan de souza, Almeida, Alessandro de M., Vieira, Lucas de Oliveira, Fonseca, Cleverson Alves, Lucas, Larissa Ferreira, Leal, Joanna, Santos, Mariane Melo, Santos, Juliana Andrade, Adorno, Elisangela, Hungria, Vania T.M., and Arruda, Maria da Gloria B.

Published
2020
Full Text
View/download PDF

42. Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Author

De Queiroz Crusoe, Edvan, Ribeiro, Glaciano, Zanella, Karla Richter, Perobelli, Leila Martins, Aranha, Milton A.F., Capra, Marcelo, Magalhães, Roberto José Pessoa, Maciel, James, Bittencourt, Rosane, Souza, Emanuella, Gaiolla, Rafael Dezen, Braga, Walter, Higashi, Fabiana, Martinez, Gracia, Hallack Neto, Abrahão Elias, De Farias, Danielle Leao Cordeiro, Farnese, Virgilio Costa, Castro, Nelson S, Tavares, Renato, Souza, Jacqueline Holanda De, Bigonha, Jandey Glória, Mattos, Ederson Roberto, Sola, Caroline, Souto Filho, Joao Tadeu, da Silva, LUiza, Araujo, Cleder Aparecido Da Silva Da Silva, Neto, Jorge Vaz Pinto, Silva, Emanuel, Hamerschlak, Nelson, Nucci, Fabio Moore, Ribeiro, Eduardo Flavio Oliveira, Cunha, Rafael, Crepaldi, Andre H, Almeida, Manuella Sampaio, Duarte, Gislaine B O, Magalhaes, Andre, Laks, Dani, Daniel, Marcos, Maiolino, Angelo, and Hungria, Vania T.M.

Published
2020
Full Text
View/download PDF

43. Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

Author

Santos, Allan de souza, Santos, Herbert Henrique de Melo, Salvino, Marco Aurelio, Silva, Sarah Queiroz, Lucas, Larissa Ferreira, Almeida, Alessandro de M., Santos, Mariane Melo, Santos, Juliana Andrade, Hungria, Vania T.M., Arruda, Maria da Gloria B., Torres, Alex, and De Queiroz Crusoe, Edvan

Published
2020
Full Text
View/download PDF

45. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.

Author

Jurczyszyn, Artur, Crusoe, Edvan, Hajek, Roman, Robak, Paweł, Raźny, Małgorzata, Zawirska, Daria, Nahi, Hareth, Liu, Jieqi, Castillo, Jorge J., Vesole, David H., Davila, Julio, Kortüm, K. Martin, Bittrich, Max, Jayabalan, David S., Vij, Ravi, Fiala, Mark, Milunovic, Vibor, Chim, C.S., Wiśniewska-Piąty, Katarzyna, and Waszczuk-Gajda, Anna

Subjects
*MULTIPLE myeloma, *STEM cell transplantation, *LACTATE dehydrogenase
Abstract

A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8-30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53-222), with 5-year OS rate of 77% (95% CI: 61.0-87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

47. Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients

Author

de Queiroz Crusoé, Edvan, Santos, Juliana, Santos, Allan, Santos, Mariane Melo, Salvino, Marco Aurelio, Adorno, Elisangela, Moura, Alessandro, Fonseca, Cleverson Alves, Queiroz, Sarah, da Gloria Bomfim, Maria, Nicanor, Jamile, Santos, Herbert Henrique, and Hungria, Vania

Published
2019
Full Text
View/download PDF

50. Superiority of Triple Combination Bortezomib + Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide + Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients

Author

De Queiroz Crusoe, Edvan, Higashi, Fabiana, Martinez, Gracia, Bittencourt, Rosane, Maiolino, Angelo, Sousa, Lais, Nunes, Renata Ferreira Marques, Ribeiro, Glaciano, Nicacio, Jandir, Zanella, Karla Richter, Magalhaes, Andre, Leao, Danielle, Pinto Neto, Jorge Vaz, Hallack Neto, Abrahão Elias, Braga, Walter, Souza, Emmanuella G, Guimaraes, Antonio Julio A.M., Durigon, Giovanna Steffenello, Laks, Dani, Kutner, Jose Mauro, Colli, Gilberto, Santucci, Rodrigo, Magalhães, Roberto José Pessoa, and Hungria, Vania T M

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results